MedTrace Logo

Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy

NCT05443178 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-07-01

No results posted yet for this study

Summary

In vitro and in vivo data show promising results of adjunctive use of Chloroquine to standard tuberculosis therapy as Chloroquine enhances animicrobial effectiveness against intracellular MTB. To date, no safety data of the concurrent use of both treatments is availble. In a phase I trial, the investigators aim to evaluate safety and tolerability of the concurrent use of Chloroquine and standard anti-TB drug in healthy volunteers.

Conditions

  • Tuberculosis Infection

Interventions

DRUG

Nivaquine ® (Chloroquine)

dose escalation and extension trial

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Marisa Kaelin, Dr. med. · University of Zurich

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2024-10-04
Completion
2025-06-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05443178 on ClinicalTrials.gov